Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea

Ji L 1 , Han P , Liu Y , Yang G , Dieu Van NK , Vijapurkar U Show all authors , Qiu R , Meininger G

Affiliations 

  • 1 Peking University People's Hospital, Peking University Diabetes Center, Beijing, China
Diabetes Obes Metab, 2015 Jan;17(1):23-31.
PMID: 25175734 DOI: 10.1111/dom.12385

Abstract

To evaluate the efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in Asian patients with type 2 diabetes mellitus (T2DM) inadequately controlled by metformin or metformin in combination with sulphonylurea.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications